Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of HEC113995PA•H2O in Healthy Subjects
NCT03943251Phase 1Completed
- Sponsor
- Sunshine Lake Pharma
- Start
- Jul 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mitizodone in major depressive disorder (MDD) (8 arms), sponsored by Sunshine Lake Pharma. Primary endpoint: Adverse events of the single ascending-dose at Day 4. Started Jul 2019; status: completed.
02
Drugs
mitizodone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03943251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03943251.